%0 Journal Article
%T Association of High miR-182 Levels with Low-Risk Prostate Cancer
%A Adam Murphy
%A Anastasiya Sapatynska
%A Andre Kajdacsy-Balla
%A Andr¨¦s M. Acosta
%A Bethany Baumann
%A Peter H. Gann
%A Ryan Deaton
%A Zachary Richards
%J Archive of "The American Journal of Pathology".
%D 2019
%R 10.1016/j.ajpath.2018.12.014
%X A subset of men with prostate cancer develops aggressive disease. We sought to determine whether miR-182, an miRNA with reported oncogenic functions in the prostate, is associated with biochemical recurrence and aggressive disease. Prostate epithelial miR-182 expression was quantified via in situ hybridization of two prostate tissue microarrays and by laser-capture microdissection of prostate epithelium. miR-182 was significantly higher in cancer epithelium than adjacent benign epithelium (P < 0.0001). The ratio of cancer to benign miR-182 expression per patient was inversely associated with recurrence in a multivariate logistic regression model (odds ratio = 0.18; 95% CI, 0.03¨C0.89; P = 0.044). Correlation of miR-182 with mRNA expression in laser-capture microdissected benign prostate epithelium was used to predict prostatic miR-182 targets. Genes that were negatively correlated with miR-182 were enriched for its predicted targets and for genes previously identified as up-regulated in prostate cancer metastases. miR-182 expression was also negatively correlated with genes previously identified as up-regulated in primary prostate tumors from African American patients, who are at an increased risk of developing aggressive prostate cancer. Taken together, these results suggest that although miR-182 is expressed at higher levels in localized prostate cancer, its levels are lower in aggressive cancers, suggesting a biphasic role for this miRNA that may be exploited for prognostic and/or therapeutic purposes to reduce prostate cancer progression
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6446228/